Bloodhound, it seems that they are able to survive and even do some outsatanding new research. They also filed new patent and have Dr. Ronald Mink's name on it. Looks like they can reduce opeattional cost to a minimum and find money do the important things, i.e. to develop a superior new product on a contract or assignment basis.
If they can maitain the same internal study high quality when they do FDA application clinical trial, it will be a game changer.
I do agree the stock has a lot of risk but the great reward potential is possible and looks better than a few months ago.
Financial statements also look a lot better.
By the way, I own Osur stocks also. I think the OTC sales will be very profitable once it is apprved.
Market Data 
Markets 
AI
